Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer - Related Studies

Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer

This study has been completed.

Study NCT00077259. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Colorectal Cancer

2	Additional conditions recognized in this trial
		Colorectal Neoplasms

3	More general conditions related to this trial
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Rectal Diseases

4	Interventions listed in this trial
		epothilone D

5	Additional drug interventions recognized in this trial
		Epothilones

6	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)